PARP inhibition by talazoparib plus DNA damage with temozolomide resulted in synergistic cell killing of MDA-MB-468 breast cancer cells that are wild-type BRCA1 and R273H mtp53 (Fig. 6a; apoptotic cells are green stained with active caspase 3 and 7). Here, CASP3 is linked to breast carcinoma.